Tenecteplase Given Through an Artery for Stroke Caused by a Blocked Medium-Sized Vessel
Tests tenecteplase delivered into an artery in adults with ischemic stroke.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)
Key facts
- Where
- Ankang, Anyang, Baise City, Changchun, Chengdu, Chongqing, Dali, Fuzhou, Guangyuan, Guilin, Guizhou, Huaibei, Jianyang, Jinan, Luoyang, Luzhou, Mianyang, Mudanjiang, Qiannan, Qingzhen, Qujing, Sanmenxia, Shangqiu, Suining, Tangshan, Wuhan, Xiangyang, Ya'an, Yichang, Zhengzhou, Zhoukou, Zhumadian, Zhuzhou, and Zigong, ChinaSee the 45 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07469293, who can take part
Where in China
- Ankang Central HospitalAnkang, ChinaNo longer taking part
- The People's Hospital of Anyang CityAnyang, ChinaNo longer taking part
- Affiliated Hospital of Youjiang Medical University for NationalitiesBaise City, ChinaNo longer taking part
- Changchun Central HospitalChangchun, ChinaNo longer taking part
- Chengdu Second People's HospitalChengdu, ChinaNo longer taking part
- Chongzhou People's HospitalChengdu, ChinaNo longer taking part
- Chonggang General HospitalChongqing, ChinaNo longer taking part
- Chongqing University Fuling HospitalChongqing, ChinaNo longer taking part
- Jiangjin Central HospitalChongqing, ChinaNo longer taking part
- The Ninth People'S Hospital of ChongqingChongqing, ChinaNo longer taking part
- The Thrid Affiliated Hospital of CQMUChongqing, ChinaNo longer taking part
- Yunyang County People's HospitalChongqing, ChinaNo longer taking part
- Dali Nationality Autonomous Prefecture HospitalDali, ChinaNo longer taking part
- The First Affiliated Hospital of Fujian MedicaluniversityFuzhou, ChinaNo longer taking part
- Guangyuan Central HospitalGuangyuan, ChinaNo longer taking part
- Guilin People's HospitalGuilin, ChinaNo longer taking part
- Qiandongnan Prefecture People's HospitalGuizhou, ChinaNo longer taking part
- Huaibei Miners General HospitalHuaibei, ChinaNo longer taking part
- The People's Hospital of Jianyang CityJianyang, ChinaNo longer taking part
- The 960th Hospital of the PLA Joint Logistics Support ForceJinan, ChinaNo longer taking part
- Luoyang Mengjin People's HospitalLuoyang, ChinaNo longer taking part
- The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaNo longer taking part
- Yiyang County People's HospitalLuoyang, ChinaNo longer taking part
- The Affiliated Hospital of Southwest Medical UniversityLuzhou, ChinaNo longer taking part
- The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical UniversityLuzhou, ChinaNo longer taking part
- Mianyang 404 HospitalMianyang, ChinaNo longer taking part
- Mudanjiang First People's HospitalMudanjiang, ChinaNo longer taking part
- The People's Hospital Of QianNanQiannan, ChinaNo longer taking part
- The First People's Hospital of QingzhenQingzhen, ChinaNo longer taking part
- Qujing Central Hospital of Yunnan ProvinceQujing, ChinaNo longer taking part
- Yellow River Sanmenxia HospitalSanmenxia, ChinaNo longer taking part
- Ninglin People's HospitalShangqiu, ChinaNo longer taking part
- The First People's Hospital of ShangqiuShangqiu, ChinaNo longer taking part
- The People's Hospital Of An JvSuining, ChinaNo longer taking part
- Yutian HospitalTangshan, ChinaNo longer taking part
- Wuhan Puren HospitalWuhan, ChinaNo longer taking part
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaNo longer taking part
- Xiangyang No.1 People's HospitalXiangyang, ChinaNo longer taking part
- Yaan People's HospitalYa'an, ChinaNo longer taking part
- Yichang Central People's HospitalYichang, ChinaNo longer taking part
- Zhengzhou Central HospitalZhengzhou, ChinaNo longer taking part
- Zhoukou Central HospitalZhoukou, ChinaNo longer taking part
- Zhumadian Central HospitalZhumadian, ChinaNo longer taking part
- Zhuzhou Central HospitalZhuzhou, ChinaNo longer taking part
- Zigong Third People's HospitalZigong, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Southwest Hospital, China
- Trial code
- NCT07469293
- Record updated
- 20 March 2026
- Original description
DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.Read full original descriptionShow less
Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial
DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.
Inclusion: Age ≥18 years old; Acute isolated intracranial medium vessel occlusion (Distal middle cerebral artery M2; M3 and M4 segments of the middle cerebral artery; A1-A4 segments of the anterior cerebral artery; P1-P3 segments of the posterior cerebral artery), confirmed by imaging, with symptom onset to randomization within 24 hours; NlHSS score ≥ 5; CT scan performed within 24 hours confirming that the ischemic lesion does not involve more than one-third of the territory supplied by the responsible vessel (no evidence of early large infarction); Patients with premorbid mRS 0 or 1; Written informed consent obtained from the participant or a legally authorized representative.
Exclusion: Already received intravenous thrombolysis; Concurrent malignant tumors or severe systemic diseases with an expected survival time of less than 90 days; Participation in another clinical interventional trial within 30 days prior to randomization or currently participating in another clinical interventional trial; Intracranial hemorrhage confirmed by cranial CT or MRI; Allergy to contrast agents or tenecteplase; Systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg, and failure to control with oral antihypertensive medications; History of bleeding within the past month (gastrointestinal or urinary tract bleeding); Severe mental disorders or inability to provide informed consent and comply with follow-up due to dementia; Genetic or acquired bleeding disorders, coagulation factor deficiencies; coagulation dysfunction, INR > 1.7, or use of novel oral anticoagulants within 48 hours; Blood glucose < 2.8 mmol/L (50 mg/dL) or > 22.2 mmol/L (400 mg/dL), platelet count < 100 × 10\^9/L; Chronic hemodialysis or severe renal insufficiency (glomerular filtration rate < 30 mL/min or serum creatinine > 220 μmol/L (2.5 mg/dL)); Planned mechanical thrombectomy; Intraoperative DSA showing vessel rupture, dissection, or contrast agent extravasation; Pregnant or breastfeeding women; Intracranial aneurysms or arteriovenous malformations; Occlusions in multiple vascular territories confirmed by CTA/MRA; Other reasons that the investigator deems inappropriate for participation in the trial.